Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025Business Wire • 04/10/25
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A BuySeeking Alpha • 03/20/25
Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 02/28/25
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025Business Wire • 02/06/25
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent GeneticsBusiness Wire • 02/04/25
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should KnowZacks Investment Research • 12/09/24
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong BuyZacks Investment Research • 11/22/24
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?Zacks Investment Research • 11/01/24
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1Business Wire • 10/31/24
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024Business Wire • 10/17/24
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/13/24
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%Zacks Investment Research • 08/13/24
Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an IssueThe Motley Fool • 08/02/24